(CercleFinance.com) – ViiV Healthcare, the global HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, announced the presentation of 29 summaries of the company’s diverse portfolio of licensed treatment and prevention options at the 24th International AIDS Conference (AIDS 2022) being held in Montreal, Canada from July 29 to August 2.
The data that will be presented includes long-term, real-world data from a portfolio of drugs, including long-acting and 2-drug regimens.
Kimberly Smith, MD, MPH, head of research and development at ViiV Healthcare, said: ‘The needs of people living with HIV continue to evolve, and the wide range of data that will be presented at AIDS 2022 illustrates the leadership and ViiV Healthcare’s commitment to innovation to meet these changing needs’.
‘We are delighted to present new data relating to HIV prevention, real-world data from long-acting and 2-drug regimens, studies aimed specifically at understanding the impact of antiretrovirals in elderly patients, and results long-term for heavily treated patients.’
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
